VYNE VYNE Therapeutics Inc.

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company is headquartered in Bridgewater, NJ.

As of 12/03/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/25/2018
Outstanding shares:  53,517,912
Average volume:  542,376
Market cap:   $49,948,267
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    92941V209
ISIN:        US92941V2097
Sedol:      BM991H5
Valuation   (See tab for details)
PE ratio:   -0.57
PB ratio:   0.83
PS ratio:   2.98
Return on equity:   -144.24%
Net income %:   -507.13%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy